TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05973656

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo saliva, mouthwash, and cheek brush collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breath Test
Description: Undergo breathalyzer testing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Breath Test
Description: Undergo breathalyzer testing
Study: NCT04386239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab Prefilled Syringe
Description: Sarilumab administration must be associated with an antiviral treatment as defined by the treatment protocol suggested by the SIMET Experts group 4 and AIFA recommendations: chloroquine 500 mg 1 tablet twice daily or hydroxychloroquine 400 mg 1 tablet twice daily in the first day and then 200 mg 1 tablet twice daily.
Study: NCT05247879

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose containing Oral Rehydration Solution (ORS)
Description: Oral rehydration solution

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sugar free - amino acid and electrolyte ORS
Description: Glucose free oral rehydration solution
Study: NCT05829941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartwatch app to deliver binge-eating CBT strategies
Description: Participants will receive a smartwatch with a pre-loaded app that will alert the participant to relevant binge-eating strategies based on their previous detected behavior.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Reminder control condition
Description: Participants will receive a smartwatch that vibrates randomly, and will be instructed the vibration is a cue not to binge eat.
Study: NCT04994132

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study: NCT05716165

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: proprioceptive knee braces
Description: The patient will perform the tests with the knee braces.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No knee brace
Description: The patient will perform the tests without the knee brace.
Study: NCT06410443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Retention enema with 10mg dexamethasone, once a day, the total course of treatment for 1 week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics, probiotics, vitamins, antidiarrheal drugs, enteral nutrition, and endoscopic argon plasma coagulation
Description: Treatment according to guideline of radiation-induced intestinal injury.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics, probiotics, vitamins, antidiarrheal drugs, enteral nutrition, and endoscopic argon plasma coagulation
Description: Treatment according to guideline of radiation-induced intestinal injury.
Study: NCT04994132

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine Tartrate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine Tartrate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray imaging
Study: NCT05876650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercises
Description: Pilates exercises starts with warm up, followed by 6 main exercises that are Swan, Swimming, Prone press up, Dart, Arm arch and Scarecow. The session will end with the cool down exercises. Each exercise will be repeated 10 times for 5 sets. Patients will be treated 3 times per week for 4 consecutive weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga will start with warm up followed by 6 yoga poses which are Warrior pose 1, Triangle pose, Child pose, Cow face pose, Bound angle pose, half bow poseThe session will end with a cool down pose. Each yoga pose will be held for 8-10 breathes Patients will be treated 3 times per week for 4 consecutive weeks.
Study: NCT05521997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaglenastat
Description: -800 mg twice per day by mouth

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation treatment
Description: * Standard of care~* External beam radiation therapy delivered daily 4 days a week and 1 day per week of brachytherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation treatment
Description: * Standard of care~* External beam radiation therapy delivered daily 4 days a week and 1 day per week of brachytherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: * Standard of care~* Weekly administration of cisplain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: * Standard of care~* Weekly administration of cisplain
Study: NCT05428696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2080
Description: Powder-in-capsule
Study: NCT04982432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orismilast
Description: Orismilast is a next generation PD4 inhibitor with demonstrated broad anti inflammatory properties
Study: NCT06346340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miebo
Description: Miebo applied in both eyes 4 times per day for approximately 30 days before cataract surgery. Following the completion of the standard follow up, approximately 30 days after cataract surgery, subjects will begin a second regimen of Miebo , 4 times per day in both eyes, for approximately 30 days.
Study: NCT06305247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPN01194
Description: IPN01194 will be taken orally over a period of 28 days (a Cycle) at the assigned dose level. The dose limiting toxicity (DLT) observation period consists of the first 28 days of treatment with IPN01194 (Cycle 1).~Participants will receive IPN01194 treatment beyond Cycle 1 until treatment is precluded by toxicity, disease progression, or upon participant's request or investigator decision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPN01194
Description: All participants will receive IPN01194 orally for 28-day cycles at one of the two dose levels determined at the end of Phase I.~Participants will receive IPN01194 treatment until treatment is precluded by toxicity, disease progression, or upon participant's request or investigator decision
Study: NCT04795713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-6402
Description: Experimental Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-6402
Description: Experimental Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-6402
Description: Experimental Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-6402
Description: Experimental Treatment
Study: NCT06291220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Intravenous Infusion
Study: NCT05851365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Bicarbonate (13C)
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance imaging
Description: Magnetic resonance imaging is a medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body
Study: NCT06291220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Intravenous Infusion
Study: NCT06291220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Intravenous Infusion
Study: NCT05428696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2080
Description: Powder-in-capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2080
Description: Powder-in-capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2080
Description: Powder-in-capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2080
Description: Powder-in-capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Powder-in-capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Powder-in-capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Powder-in-capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Powder-in-capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Powder-in-capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Powder-in-capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Powder-in-capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Powder-in-capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Powder-in-capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Powder-in-capsule
Study: NCT06231472

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peroperative inferior vena cava measurement
Description: peroperative inferior vena cava measurement
Study: NCT05875610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine 75 MG
Description: Venlafaxine 75 mg extended release capsules for a 7-days duration
Study: NCT05023798

Intervention type: DEVICE
Intervention: ATD (device test)
Description: Medical device test (no intervention)

Intervention type: DEVICE
Intervention: ATD (device test)
Description: Medical device test (no intervention)

Intervention type: DEVICE
Intervention: ATD (device test)
Description: Medical device test (no intervention)
Study: NCT05875610

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin 400 mg
Description: Gabapentin 400 mg capsules
Study: NCT05023798

Intervention type: DEVICE
Intervention: ATD (device test)
Description: Medical device test (no intervention)

Intervention type: DEVICE
Intervention: ATD (device test)
Description: Medical device test (no intervention)

Intervention type: DEVICE
Intervention: ATD (device test)
Description: Medical device test (no intervention)

Intervention type: DEVICE
Intervention: ATD (device test)
Description: Medical device test (no intervention)

Intervention type: DEVICE
Intervention: ATD (device test)
Description: Medical device test (no intervention)

Intervention type: DEVICE
Intervention: ATD (device test)
Description: Medical device test (no intervention)
Study: NCT04841746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical therapy that include a standardized cycling training with functional electrical stimulation
Description: Immediately after the discharge of the intensive care unit, patient with a severe form of the COVID-19 will be admitted in the rehabilitation hospital. Rehabilitation will consist in physical therapy twice a day, 30 minutes, 5 days a week. One session will be dedicated to a standardized cycling training (TECHNOGYM RECLINE EXCITE 700). All participants will follow the same 4-week rehabilitation protocol representing a total of 1200 minutes. Participants randomized in the experimental group will received functional electrical stimulation administered to surface electrodes attached to lower limb muscles (quadriceps, hamstrings, gluteus maximus and triceps). Electrical stimulation will be delivered appropriately to the muscle during cycling regarding the angle of the pedal by a stimulator (Motimove-8 de 3Fit Fabricando Faber).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy that include a standardized cycling training with no additional functional electrical stimulation
Description: Immediately after the discharge of the intensive care unit, patient with a severe form of the COVID-19 will be admitted in the rehabilitation hospital. Rehabilitation will consist in physical therapy twice a day, 30 minutes, 5 days a week. One session will be dedicated to a standardized cycling training (TECHNOGYM RECLINE EXCITE 700). All participants will follow the same 4-week rehabilitation protocol representing a total of 1200 minutes. Participants randomized in the control group will received no additional functional electrical stimulation during cycling.
Study: NCT04473326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinforcement Learning
Description: Participants in the intervention arm will receive up to daily, tailored text messages based on their electronic pill bottle-measured adherence. Given the participants' baseline characteristics and time-varying responses to the messages, a reinforcement learning algorithm will deliver different text messages and adapt over time to determine which type of messaging works best for each individual participant.
Study: NCT06291220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-453
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-453
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-453
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-453
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-453
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-453
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-453
Description: Oral; Tablet
Study: NCT05394272

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Therapy - Pranic Healing
Description: Energy therapy - Non invasive non touch and non pharmacological - 100% natural complementary therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Therapy - Pranic Healing
Description: Energy therapy - Non invasive non touch and non pharmacological - 100% natural complementary therapy
Study: NCT05475379

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Typhoid Vi polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT)
Description: Typhoid Vi-polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT) Typhocon will be manufactured by Incepta Vaccine Limited

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typhoid Vi polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT)
Description: Typhoid Vi-polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT) Typhocon will be manufactured by Incepta Vaccine Limited
Study: NCT05646797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2074
Description: intravenous (IV) infusion
Study: NCT05280080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: Do the maximum number of repetitions of externally-resisted (50% 1RM) knee extensions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance exercise
Description: Do the maximum number of repetitions of externally-resisted (50% 1RM) knee extensions.
Study: NCT05193734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertagen®
Description: Schedule:~Group Pertagen will receive two doses of Pertagen®. (one vaccination on Day 0 and 6 months later for each volunteer.)~Mode of Administration:~Intramuscular injection into the deltoid region of the upper extremity, using a syringe with a 1 to 1.5 inch #25-gauge sterile needle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Revaxis®
Description: Schedule:~Group Control will receive one dose of Revaxis® on Day 0 followed by 1 dose of Pertagen® 6 months later for each volunteer.~Mode of Administration:~Intramuscular injection into the deltoid region of the upper extremity, using a syringe with a 1 to 1.5 inch #25-gauge sterile needle.
Study: NCT06103383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Controlled ovarian stimuation
Description: 3 days stimullation protocol using hMG-HP

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oocyte pick up
Description: Surgical oocyte pick up without triggering

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oocyte in vitro maturation
Description: In vitro maturation procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oocyte in vitro activation
Description: In vitro oocyte activation procedure
Study: NCT05435534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ActiveFLS intervention
Description: * A comprehensive geriatric assessment with a multicomponent physical exercise program guideline based on ActiveHip+ for 3 months. In the subsequent revisions, exercise guidelines from the Vivifrail program will be given~* A protocolized nutritional intervention will be carried out. In case of oral nutritional supplementation, supplements enriched in β-hydroxy-β-methylbutyrate (HMB) will be selected~* Osteoporosis treatments according to national guideline~* A review and adaptation of the treatment will be carried out according to the STOPP (Screening Tool of Older Persons' Prescriptions) and START (Screening Tool to Alert to Right Treatment) criteria~* An approach will be made to the patient's mood and fear of falling. In case of depression, both pharmacological and non-pharmacological approaches will be assessed~* Screening for cognitive impairment will be performed. In the event of evidence of memory problems, a recommendations for cognitive stimulation will be delivered

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care group
Description: Participants randomly assigned to the usual care group will receive normal outpatient care, including physical rehabilitation when needed.
Study: NCT06228196

Intervention type: DEVICE
Intervention: Simultaneous cortico-spinal magnetic resonance imaging, Serum
Description: Simultaneous cortico-spinal magnetic resonance imaging data were collected in a strong magnetic field and collected the serum of participants.

Intervention type: DEVICE
Intervention: Simultaneous cortico-spinal magnetic resonance imaging, Serum
Description: Simultaneous cortico-spinal magnetic resonance imaging data were collected in a strong magnetic field and collected the serum of participants.
Study: NCT05521919

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sympathetic Nervous System Activation
Description: Participants will complete a task that increases sympathetic nervous system activation.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: No-stress
Description: Participants will complete a task that will not affect their sympathetic nervous system activity.
Study: NCT05793645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: personalized care plan
Description: Algorithm that defines personalized care plan
Study: NCT06114641

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin sodium injection
Description: Originator Enoxaparin with a trade name is Lovenox.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin sodium injection
Description: Originator Enoxaparin with a trade name is Lovenox.
Study: NCT06548620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD06-04 cell infusion
Description: CAR T Cells
Study: NCT05646797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2074
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2074
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2074
Description: intravenous (IV) infusion
Study: NCT05982171

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exo + TSCS
Description: Participants will receive TSCS delivered with the ONWARD Lift system at 1ms using a 10kHz carrier frequency delivered at 30Hz, with an amplitude set for each participant based on their ability to increase voluntary movement output.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Exo + Sham
Description: The ONWARD Lift system will also be used to deliver sham stimulation which will also be delivered at 1ms using a 10kHz carrier frequency delivered at 30Hz, and an amplitude of 1ma which has been used in other sham stimulation protocols and is not sufficient to induce activation of lumbosacral neuronal pools.
Study: NCT04967950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 MG
Description: Secukinumab 150 mg s.c. with loading dose at baseline, week 1,2,3,4 and then every 4 weeks from week 5 up to 12 weeks. After which, if MASEI ultrasound enthesitis score improvement is less than 50%, Secukinumab 150 mg will be with a switch to 300 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 MG
Description: Methotrexate 15 mg po. every week up to 12 weeks. After which, if MASEI ultrasound enthesitis score improvement is less than 50%, methotrexate with a switch to Secukinumab 150 mg at 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: methotrexate
Study: NCT05877599

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous, engineered T Cells targeting TP53 R175H
Description: * Pre-conditioning by non-myeloablative chemotherapy with fludarabine and cyclophosphamide~* Single infusion TCR T cells~* Post-infusion recombinant interleukin-2 (rIL-2)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous, engineered T Cells targeting TP53 R175H
Description: * Pre-conditioning by non-myeloablative chemotherapy with fludarabine and cyclophosphamide~* Single infusion TCR T cells~* Post-infusion recombinant interleukin-2 (rIL-2)
Study: NCT05091203

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: To investigate role of vitamin D in follicular maturation and number of mature follicles which help in the success of IVF procedure

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Vitamin D
Description: To investigate role of vitamin D in follicular maturation and number of mature follicles which help in the success of IVF procedure
Study: NCT05877599

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous, engineered T Cells targeting TP53 R175H
Description: * Pre-conditioning by non-myeloablative chemotherapy with fludarabine and cyclophosphamide~* Single infusion TCR T cells~* Post-infusion recombinant interleukin-2 (rIL-2)
Study: NCT06653023

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Universal CAR-T cells injection for treating HCC and NSCLC
Description: A novel universal CAR-T platform to treat cancer patients